Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo A Olivera

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Journal of the Canadian Association of Gastroenterology|February 5, 2024
Biomarkers That Predict Crohn's Disease OutcomesPablo A Olivera, Mark S Silverberg
Gastroenterology|March 8, 2025
ReplyPablo A Olivera, Sun-Ho Lee, Kenneth Croitoru
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|July 5, 2022
Prolonged Intestinal Transit Time and Its Relation with Capsule Endoscopy Diagnostic YieldJuan Lasa, Gustavo Cernadas, Pablo A Olivera, et al.
The Lancet. Gastroenterology & Hepatology|March 12, 2022
Ranking treatments in the network meta-analysis should consider the certainty of evidence - Authors' replyJuan S Lasa, Pablo A Olivera, Laurent Peyrin-Biroulet
The Lancet. Gastroenterology & Hepatology|December 2, 2021
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysisJuan S Lasa, Pablo A Olivera, Silvio Danese, et al.
Drug Safety|March 5, 2021
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-AnalysisJuan S Lasa, Pablo A Olivera, Stefanos Bonovas, et al.
Gastroenterology|January 12, 2020
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-AnalysisPablo A Olivera, Juan S Lasa, Stefanos Bonovas, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2023
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugsPablo A Olivera, Juan S Lasa, Giovanni Peretto, et al.
The American Journal of Gastroenterology|January 29, 2025
Comparative Improvement in Health-Related Quality of Life With Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-AnalysisPablo A Olivera, María L Parks, Ignacio Zubiaurre, et al.
Therapeutic Advances in Gastroenterology|May 1, 2023
IBD barriers across the continents: a continent-specific analysis: Latin AmericaNatália Sousa Freitas Queiroz, Camilla de Almeida Martins, Abel Botelho Quaresma, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Journal of the Canadian Association of Gastroenterology|February 5, 2024
Biomarkers That Predict Crohn's Disease OutcomesPablo A Olivera, Mark S Silverberg
Gastroenterology|March 8, 2025
ReplyPablo A Olivera, Sun-Ho Lee, Kenneth Croitoru
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|July 5, 2022
Prolonged Intestinal Transit Time and Its Relation with Capsule Endoscopy Diagnostic YieldJuan Lasa, Gustavo Cernadas, Pablo A Olivera, et al.
The Lancet. Gastroenterology & Hepatology|March 12, 2022
Ranking treatments in the network meta-analysis should consider the certainty of evidence - Authors' replyJuan S Lasa, Pablo A Olivera, Laurent Peyrin-Biroulet
The Lancet. Gastroenterology & Hepatology|December 2, 2021
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysisJuan S Lasa, Pablo A Olivera, Silvio Danese, et al.
Drug Safety|March 5, 2021
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-AnalysisJuan S Lasa, Pablo A Olivera, Stefanos Bonovas, et al.
Gastroenterology|January 12, 2020
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-AnalysisPablo A Olivera, Juan S Lasa, Stefanos Bonovas, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2023
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugsPablo A Olivera, Juan S Lasa, Giovanni Peretto, et al.
The American Journal of Gastroenterology|January 29, 2025
Comparative Improvement in Health-Related Quality of Life With Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-AnalysisPablo A Olivera, María L Parks, Ignacio Zubiaurre, et al.
Therapeutic Advances in Gastroenterology|May 1, 2023
IBD barriers across the continents: a continent-specific analysis: Latin AmericaNatália Sousa Freitas Queiroz, Camilla de Almeida Martins, Abel Botelho Quaresma, et al.
Pageof 4